Idiopathic pulmonary fibrosis is a disease of unknown etiology characterized pathologically by a chronic inflammatory process that precedes and likely controls the alterations in connective tissue matrix that eventually destroys the normal lung architecture. The mechanisms involved in this process are not known but a complex cell-cell interactive sequence, involving principally neutrophils, lymphocytes, macrophages and fibroblast is believed to be responsible. The long-term objectives of this project are to determine what alterations in cellular composition, function and trafficking occurs in the lung parenchyma of patients with idiopathic pulmonary fibrosis and to relate these alterations to the disease stage, prognosis, and therapeutic responsiveness.
Our specific aims are to: (1) correlate noninvasive methods, primarily bronchoalveolar lavage and a new lung scanning technique, Inulin- labelled neutrophils (or monocytes), with clinical and morphological parameters to determine if (and how) these methods are to be used in diagnosis, staging and predicting therapeutic response; (2) to utilize functional assays and immunohistochemical techniques to characterize the cells and extracellular matrix of the lung parenchyma and to correlate these findings with those obtained by BAL and with the clinical parameter. We expect that these investigations will answer several questions: What are the features of IPF that determine disease activity and therapeutic responsiveness? Is lavage analysis a sensitive and specific method for the detection of these features in all patients with IPF? How can lavage be used most effectively, especially its relationship to other measures of disease activity such as immune complexes? Is the inflammatory response in the lavage """"""""in phase"""""""" with that found in the lung parenchyma? Can the extent and severity of the disease be measured/assessed by semiquantitative routine histologic methods or does it require morphometric techniques?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL027353-09
Application #
3879916
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1990
Total Cost
Indirect Cost
Name
National Jewish Health
Department
Type
DUNS #
City
Denver
State
CO
Country
United States
Zip Code
80206
Kinder, Brent W; Brown, Kevin K; McCormack, Francis X et al. (2009) Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 135:1557-1563
Kinder, Brent W; Brown, Kevin K; Schwarz, Marvin I et al. (2008) Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 133:226-32
Perez, Rafael L; Kimani, Anthony P; King Jr, Talmadge E et al. (2007) Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis. Respiration 74:297-303
Schwarz, Marvin I; Albert, Richard K (2004) ""Imitators"" of the ARDS: implications for diagnosis and treatment. Chest 125:1530-5
Vourlekis, Jason S; Schwarz, Marvin I; Cool, Carlyne D et al. (2002) Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. Am J Med 112:490-3
Inoue, Yoshikazu; King Jr, Talmadge E; Barker, Elizabeth et al. (2002) Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med 166:765-73
King Jr, T E; Schwarz, M I; Brown, K et al. (2001) Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 164:1025-32
King Jr, T E; Tooze, J A; Schwarz, M I et al. (2001) Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164:1171-81
Glazer, C S; Cohen, L B; Schwarz, M I (2001) Acute eosinophilic pneumonia in AIDS. Chest 120:1732-5
Martinez, J A; Nishimura, C; Guatura, S B et al. (2001) Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. Rheumatol Int 21:122-6

Showing the most recent 10 out of 220 publications